Affymax (EM)【AFFY】銘柄情報

Affymax Inc (EM) (AFFY) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

0.0013

( - )

買値

0.00

売値

0.00

出来高

0.00 日の範囲 0.00

0.0001 52 週間の範囲 0.003

時価総額

96.837k

前日終値

0.0013

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

US$ 3,012

発行済株式数

74,490,095

配当利回り

PER

0.02

1 株当たり利益 (EPS)

0.09

歳入

42k

純利益

3.07M

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York. Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

セクター

Healthcare

業界

Biotechnology & Life Sciences

本社

New York, United States

設立

2026

Affymax Inc (EM) is listed in the Healthcare sector of the その他OTC with ticker AFFY. The last closing price for Affymax (EM) was US$0. Over the last year, Affymax (EM) shares have traded in a share price range of US$ 0.0001 to US$ 0.003.

Affymax (EM) currently has 74,490,095 shares in issue. The market capitalisation of Affymax (EM) is US$96,837.12 . Affymax (EM) has a price to earnings ratio (PE ratio) of 0.02.

Affymax Adopts Tax Benefit Preservation Plan to Protect Net Operating Loss Carryforwards

Affymax, Inc. (OTCQB: AFFY) announced today that its Board of Directors has adopted a Tax Benefit Preservation Plan, or Rights Plan, in an...

Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a New Director and Chief Executive Officer

Affymax, Inc. (OTCQB: AFFY) today announced that its Board of Directors has declared a special cash distribution to shareholders in the amount...

Xstelos Announces Intention To Vote Against Affymax's Plan Of Liquidation At September 23, 2014 Special Meeting of Shareholders

Xstelos Announces Intention To Vote Against Affymax's Plan Of Liquidation At September 23, 2014 Special Meeting of Shareholders PR Newswire NEW...

Pomerantz Law Firm Announces Summary Notice of Pendency & Proposed Settlement of Affymax, Inc. Class Action & Settlement Hear...

TO: ALL PERSONS AND ENTITIES THAT PURCHASED AFFYMAX, INC., (“AFFYMAX”) COMMON STOCK DURING THE PERIOD FROM AUGUST 8, 2012 THROUGH FEBRUARY...

Affymax Reports Second Quarter 2014 Financial Results

Affymax, Inc. (OTCQB:AFFY) today reported financial results for the second quarter ending June 30, 2014. The net income for the second...

Affymax Board Announces Decision to Dissolve the Company

Affymax, Inc. (AFFY), a biopharmaceutical company, today announced that its Board of Directors has approved the liquidation and dissolution of...

OTC Daily Trading Focus List: Axxess Pharma, Inc. Petvivo Holdings, Inc. Integrated Cannabis Solutions, Inc. BreedIT Corp, Af...

OTC Daily Trading Focus List: Axxess Pharma, Inc. Petvivo Holdings, Inc. Integrated Cannabis Solutions, Inc. BreedIT Corp, Affymax, Inc. PR...

Affymax and Takeda Announce Termination of Omontys® (peginesatide) Product Collaboration and License Agreement

Takeda will withdraw the Omontys U.S. New Drug Application (NDA) Affymax, Inc. and Takeda Pharmaceutical Company Limited (Takeda) Osaka...

Affymax Announces Update on Listing, Senior Leadership and Board Changes

As previously announced, on May 28, 2013, Affymax, Inc. (the “Company”) received a determination letter (the “Determination Letter”) from...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.0002	18.1818181818	0.0011	0.0013	0.001	1838	0.00124297	CS
4	0.0003	30	0.001	0.0013	0.001	2321	0.00107649	CS
12	0.0003	30	0.001	0.0013	0.001	3084	0.00108175	CS
26	0.0005	62.5	0.0008	0.0014	0.0008	5321	0.00092967	CS
52	0.0005	62.5	0.0008	0.003	0.0001	12630	0.0011373	CS
156	-0.0028	-68.2926829268	0.0041	0.0407	0.0001	11359	0.00104914	CS
260	-0.05575	-97.7212971078	0.05705	0.073	0.0001	18048	0.01597504	CS